GLP-1 pregnancy and muscle loss claims, fact-checked

What did @steven actually say?

The video clips Jessie Inchauspé making two distinct arguments about GLP-1 medications. First, that taking these drugs during pregnancy is "very dangerous" because they suppress hunger at a time when caloric and nutrient needs increase. Second, that GLP-1 users lose significant muscle alongside fat, and when they stop, they regain only fat, leaving them in "a worse body composition place than before." The proposed fix: eat roughly 100 grams of protein daily to preserve muscle mass.

These are not fringe concerns. Both points have real scientific traction, though the framing in the video is messier than the underlying evidence.

Does the science back this up?

On pregnancy: yes, broadly. On muscle loss and rebound: partially, but with important nuance the video glosses over.

GLP-1 receptor agonists are classified as FDA Pregnancy Category C or equivalent, meaning animal studies show fetal harm and human data is insufficient. The FDA and major prescribing guidelines explicitly advise discontinuing semaglutide and tirzepatide at least two months before a planned pregnancy. The concern about appetite suppression during pregnancy is clinically legitimate. A 2023 review by Cesta et al. in JAMA Internal Medicine flagged the near-total absence of safety data for GLP-1 use in pregnant populations.

On muscle loss: the STEP trials (Wilding et al., 2021, New England Journal of Medicine) showed that roughly 39% of total weight lost on semaglutide came from lean mass, which is consistent with weight loss in general, not uniquely worse than other methods. The "you only gain fat back" claim is a real phenomenon documented in the STEP 1 extension data, but it is not absolute.

What did they get wrong (or right)?

The pregnancy warning is largely correct and probably underemphasized in popular discourse. Credit where it is due.

The muscle loss framing, however, is misleading by omission. The video implies GLP-1s uniquely destroy muscle. They do not. Any caloric deficit, including from dieting without medication, produces lean mass loss. A 2023 meta-analysis by Blonde et al. in Diabetes, Obesity and Metabolism found lean mass loss on GLP-1s was proportionally similar to what you see with equivalent caloric restriction alone. The drugs are not special villains here.

The "only gain fat back" claim is based on real discontinuation data but is stated as inevitable. It is not. Resistance training during treatment substantially changes the outcome. A 2024 study by Aronne et al. in Obesity found that participants who combined semaglutide with structured exercise preserved significantly more lean mass than those on the drug alone.

The 100 grams of protein recommendation is reasonable as general nutrition guidance, but presenting it as a precise therapeutic dose for GLP-1 users without clinical context is the kind of thing that should come from a registered dietitian, not a podcast clip.

What should you actually know?

If you are pregnant or planning to become pregnant, GLP-1 medications should not be on the table right now. The lack of safety data is not a technicality, it reflects a genuine knowledge gap. Talk to your OB.

If you are using GLP-1s for weight management, muscle loss is a real and documented side effect, but it is manageable. Resistance training is the most evidence-supported intervention. Protein intake matters too, but the "100 grams" figure is a general target, not a clinical prescription, and individual needs vary by body weight and activity level.

The rebound weight gain after stopping is real and documented. That does not mean the drugs are harmful for everyone or that discontinuation always leads to worse outcomes. It does mean that GLP-1 treatment should be part of a longer conversation with a physician about lifestyle, not a standalone fix.